SCHEDULE 13D
Explanatory Note:
This joint statement on Schedule 13D/A (this “Statement”) is filed with respect to the Common Stock, par value $0.0001 per share (“Common Stock”), of Tenaya Therapeutics, Inc., a Delaware corporation (the “Issuer”). This Amendment No. 1. (this “Amendment”) supplements and amends the Schedule 13D relating to the Common Stock of the Issuer that was filed with the Commission on December 1, 2022 (the “Original Schedule 13D”), previously reported on a Schedule 13G filed with the Commission on February 11, 2022 (the “Schedule 13G”). The Schedule 13G was filed pursuant to Rule 13d-1(d) of the Securities Exchange Act. This Amendment is being filed to update the aggregate percentage of the Common Stock owned by the Reporting Persons due to purchases of shares of Common Stock since the date of the filing of the Original Schedule 13D. Only those items that are reported are hereby amended; all other items reported in the Original Schedule 13D remain unchanged. Capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Original Schedule 13D. Information given in response to each item shall be deemed incorporated by reference in all other items as applicable.
Item 3. Source and Amount of Funds or Other Consideration
Item 3 of the Schedule 13D is hereby amended by adding the following as the last paragraphs thereof:
On January 17, 2023, TCG Opportunity III LP purchased 49,463 shares of Common Stock for a weighted-average purchase price of $2.4947 per share and an aggregate purchase price of $123,395.35.
On January 18, 2023, TCG Opportunity III LP purchased 135,688 shares of Common Stock for a weighted-average purchase price of $2.5163 per share and an aggregate purchase price of $341,431.71.
On January 19, 2023, TCG Opportunity III LP purchased 69,739 shares of Common Stock for a weighted-average purchase price of $2.4979 per share and an aggregate purchase price of $174,201.05.
On February 8, 2023, TCG Opportunity III LP purchased 1,500,000 shares of Common Stock for a purchase price of $2.60 per share and an aggregate purchase price of $3,900,000.00.